Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

Gilead Sciences easily beat third-quarter forecasts late Wednesday, and raised its outlook in a move that could bolster ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2024 results on Nov. 6, after market close. The ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost ...